MCID: HYP085
MIFTS: 42

Hypothalamic Disease

Categories: Rare diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Hypothalamic Disease

MalaCards integrated aliases for Hypothalamic Disease:

Name: Hypothalamic Disease 12 14
Hypothalamic Diseases 42 69
Hypothalamic Dysfunction Syndromes 69
Hypothalamic Dysfunction 50
Hypothalamic Disorder 52

Classifications:



External Ids:

Disease Ontology 12 DOID:1931
MeSH 42 D007027
ICD10 33 E23.3
UMLS 69 C0020655

Summaries for Hypothalamic Disease

NIH Rare Diseases : 50 hypothalamic dysfunction refers to a condition in which the hypothalamus is not working properly. the hypothalamus produces hormones that control body temperature, hunger, moods, release of hormones from many glands such as the pituitary gland, sex drive, sleep, and thirst. the signs and symptoms patients have vary depending on the hormones missing. a number of different causes including anorexia, bleeding, genetic disorder, tumors, and more have been linked to hypothalamic dysfunction. treatment depends on the cause of the hypothalamic dysfunction. last updated: 4/13/2010

MalaCards based summary : Hypothalamic Disease, also known as hypothalamic diseases, is related to rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome and anophthalmia cleft lip palate hypothalamic disorder. An important gene associated with Hypothalamic Disease is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and brain, and related phenotypes are endocrine/exocrine gland and liver/biliary system

Wikipedia : 72 Hypothalamic disease is a disorder presenting primarily in the hypothalamus, which may be caused by... more...

Related Diseases for Hypothalamic Disease

Diseases related to Hypothalamic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.0
2 anophthalmia cleft lip palate hypothalamic disorder 11.9
3 rohhad 11.7
4 shapiro syndrome 10.9
5 fryns microphthalmia syndrome 10.9
6 x-linked lissencephaly with abnormal genitalia 10.8
7 froelich syndrome 10.6
8 euthyroid sick syndrome 10.4 CRH PRL
9 chronic dacryoadenitis 10.4 CRH PRL
10 prostate leiomyoma 10.3 GNRH1 PRL
11 adenomatoid tumor 10.3 GNRH1 PRL
12 internal hemorrhoid 10.3 GNRH1 PRL
13 porokeratosis 10.3 GNRH1 PRL
14 hypoglycemic coma 10.3 CRH GNRH1
15 g6pc3 deficiency 10.2 GH1 PRL
16 combined t cell and b cell immunodeficiency 10.2 GH1 PRL
17 retroperitoneal sarcoma 10.2 GNRH1 PRL
18 pityriasis rotunda 10.2 GH1 PRL
19 pituitary adenoma, prolactin-secreting 10.2 GH1 PRL
20 osseous heteroplasia, progressive 10.2 GH1 PRL
21 adamantinous craniopharyngioma 10.2 GNRH1 PRL
22 haverhill fever 10.2 GNRH1 PRL
23 47,xyy syndrome 10.2 GH1 PRL
24 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 10.2 GH1 GHRH
25 worth's syndrome 10.2 GH1 PRL
26 aromatase excess syndrome 10.1 GH1 GNRH1
27 avoidant personality disorder 10.1 GNRH1 PRL
28 presenile dementia, kraepelin type 10.1 GH1 GNRH1
29 kowarski syndrome 10.1 GH1 GHRH
30 dwarfism familial with muscle spasms 10.1 GH1 GHRH
31 primary hypomagnesemia 10.1 GH1 GHRH
32 renal pelvis carcinoma 10.1 CRH POMC
33 febrile infection-related epilepsy syndrome 10.1 CRH POMC
34 dressler's syndrome 10.1 CRH POMC
35 immunodeficiency, common variable, 5 10.1 GHRH PRL
36 autoimmune disease of central nervous system 10.0 CRH POMC
37 early-onset parkinson disease 10.0 CRH POMC
38 traumatic glaucoma 10.0 CRH POMC
39 immune system organ benign neoplasm 10.0 POMC PRL
40 grubben de cock borghgraef syndrome 10.0 GH1 GHRH
41 adrenoleukodystrophy 10.0 GNRH1 PRL
42 keratosis 10.0 CRH POMC
43 posterior uveal melanoma 10.0 CRH POMC
44 capillary disease 9.9 POMC PRL
45 fibrolamellar carcinoma 9.9 POMC PRL
46 adrenal cortical adenocarcinoma 9.9 CRH POMC
47 acute female pelvic peritonitis 9.9 POMC PRL
48 benign peritoneal mesothelioma 9.9 GNRH1 POMC
49 neurogenic arthropathy 9.9 GHRH POMC
50 hypermobility syndrome 9.9 CRH POMC

Graphical network of the top 20 diseases related to Hypothalamic Disease:



Diseases related to Hypothalamic Disease

Symptoms & Phenotypes for Hypothalamic Disease

MGI Mouse Phenotypes related to Hypothalamic Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 CRH GHRH GNRH1 POMC PRL
2 liver/biliary system MP:0005370 9.02 CRH GHRH GNRH1 POMC PRL

Drugs & Therapeutics for Hypothalamic Disease

Drugs for Hypothalamic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 370)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-23-7 5754 657311
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
6
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
7
Cosyntropin Approved Phase 4,Phase 1 16960-16-0 16129617
8
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
9 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
14 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
15
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
16
Zinc Approved Phase 4,Phase 3,Early Phase 1 7440-66-6 32051 23994
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Morphine Approved, Investigational Phase 4 57-27-2 5288826
23
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
24
Quinagolide Approved Phase 4 97805-50-0, 87056-78-8 105105
25
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
26
Sodium oxybate Approved Phase 4 502-85-2 5360545
27
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
28
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
29
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
30
Liraglutide Approved Phase 4 204656-20-2 44147092
31
Cefazolin Approved Phase 4 25953-19-9 656510 33255
32
Cefdinir Approved Phase 4 91832-40-5 6915944
33
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
34
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
35
Sulfamethoxazole Approved Phase 4 723-46-6 5329
36
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
39
Butyric Acid Experimental Phase 4,Phase 2,Phase 1,Early Phase 1 107-92-6 264
40
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
41 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Early Phase 1
43 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
44 Cortisol succinate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 624)

id Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
4 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Unknown status NCT00851942 Phase 4 Synacthen (Tetracosactrin)
5 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
6 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
7 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
8 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
9 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
10 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
11 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
12 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
13 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
14 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
15 Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery Completed NCT00500227 Phase 4
16 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
17 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
18 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
19 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
20 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
21 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
22 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
23 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
24 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
25 Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Completed NCT01014793 Phase 4 cabergoline
26 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
27 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
28 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
29 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
30 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
31 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
32 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
33 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
34 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
35 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
36 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
37 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Human Growth Hormone;Placebo
38 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
39 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
40 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
41 IGF1 Generation Test Completed NCT00145457 Phase 4
42 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
43 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
44 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
45 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
46 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
47 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
48 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
49 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
50 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR

Search NIH Clinical Center for Hypothalamic Disease

Cochrane evidence based reviews: hypothalamic diseases

Genetic Tests for Hypothalamic Disease

Anatomical Context for Hypothalamic Disease

MalaCards organs/tissues related to Hypothalamic Disease:

39
Pituitary, Testes, Brain, Hypothalamus, Bone, Thyroid, Ovary

Publications for Hypothalamic Disease

Articles related to Hypothalamic Disease:

(show all 11)
id Title Authors Year
1
Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. ( 23318724 )
2013
2
Hypothalamic disease: neurosecretory dysfunction and parasellar lesions. ( 9174692 )
1997
3
Neurologic manifestations of hypothalamic disease. ( 1480755 )
1992
4
Hypothalamic disease in association with dysgenesis of the corpus callosum. ( 2813236 )
1989
5
Hypothalamic disease presenting as amenorrhoea: value of computed tomography. ( 4084469 )
1985
6
Radiological aspects of pituitary--hypothalamic disease. ( 330035 )
1977
7
Evidence that acromegaly is not a hypothalamic disease. ( 4363384 )
1973
8
A comparative study of endocrine tests in hypothalamic disease. Circadian periodicity of plasma 11-OHCS levels, plama 11-OHCS and growth hormone response to insulin hypoglycemia and metyrapone responsiveness. ( 5697039 )
1968
9
Evaluation of ACTH reserve in pituitary-hypothalamic disease. ( 4288690 )
1966
10
Dysrhythmia associated with proved hypothalamic disease. Fourteen- and six-per-second dysrhythmia. ( 14465902 )
1962
11
Endocrine and other clinical manifestations of hypothalamic disease; a survey of 60 cases, with autopsies. ( 13130650 )
1954

Variations for Hypothalamic Disease

Expression for Hypothalamic Disease

Search GEO for disease gene expression data for Hypothalamic Disease.

Pathways for Hypothalamic Disease

GO Terms for Hypothalamic Disease

Cellular components related to Hypothalamic Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.55 CRH GH1 GHRH GNRH1 POMC
2 extracellular region GO:0005576 9.1 CRH GH1 GHRH GNRH1 POMC PRL
3 endosome lumen GO:0031904 8.96 GH1 PRL

Biological processes related to Hypothalamic Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.54 GHRH GNRH1 POMC
2 positive regulation of cAMP biosynthetic process GO:0030819 9.4 CRH GHRH
3 positive regulation of multicellular organism growth GO:0040018 9.32 GH1 GHRH
4 positive regulation of JAK-STAT cascade GO:0046427 9.26 GH1 PRL
5 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.16 GH1 PRL
6 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.96 GH1 GHRH
7 female pregnancy GO:0007565 8.8 CRH GNRH1 PRL

Molecular functions related to Hypothalamic Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 CRH GH1 GNRH1 POMC PRL
2 prolactin receptor binding GO:0005148 8.96 GH1 PRL
3 neuropeptide hormone activity GO:0005184 8.85 CRH

Sources for Hypothalamic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....